Completed PHASE4 INTERVENTIONAL NCT00014001

CATIE- Schizophrenia Trial

Comparative Effectiveness of Antipsychotic Medications in Patients With Schizophrenia (CATIE Schizophrenia Trial)

Sponsor: National Institute of Mental Health (NIMH)

Interventions clozapine fluphenazine decanoate olanzapine perphenazine quetiapine risperidone ziprasidone

Updated 6 times since 2017 Last updated: Jun 16, 2015 Started: Dec 31, 2000 Completion: Dec 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Schizophrenia and is currently completed. National Institute of Mental Health (NIMH) leads this study, which shows 6 recorded versions since 2000 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Dec 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute of Mental Health (NIMH)

Data source: National Institute of Mental Health (NIMH)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Athens, United States , Atlanta, United States , Beachwood, United States , Boca Raton, United States , Boston, United States , Brooklyn, United States , Butner, United States , Chapel Hill, United States , Charleston, United States and 37 more locations